Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
<strong>Background</strong> Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and...
主要な著者: | Thriemer, K, Degaga, TS, Christian, M, Alam, MS, Ley, B, Hossain, MS, Kibria, MG, Tego, TT, Abate, DT, Weston, S, Karahalios, A, Rajasekhar, M, Simpson, JA, Rumaseb, A, Mnjala, H, Lee, G, Anose, RT, Kidane, FG, Woyessa, A, Baird, K, Sutanto, I, Hailu, A, Price, RN |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BioMed Central
2022
|
類似資料
-
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial
著者:: Thriemer, K, 等
出版事項: (2022) -
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
著者:: Kamala Thriemer, 等
出版事項: (2022-05-01) -
Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned
著者:: Degaga, TS, 等
出版事項: (2020) -
Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned
著者:: Tamiru S. Degaga, 等
出版事項: (2020-06-01) -
Adapting international clinical trials during COVID-19 and beyond
著者:: Thriemer, K, 等
出版事項: (2023)